The invention relates to artificial transcription factors comprising polydactyl zinc finger proteins targeting promoters of genes involved in maladapted wound healing in the eye. Such artificial transcription factors are useful for the treatment of fibrocontractive retinal disorders, such asepiretinal gliosis, proliferative vitreoretinopathy, proliferative diabetic retinopathy and epiretinal membrane, and for the treatment of fibroplasia associated with glaucoma surgery.
